- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
EP: 5.Key Highlights from EV-302 Study at ESMO 2023
EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023
EP: 7.Future Opportunities in Genitourinary Cancers
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses results from the THOR-2 study of erdafitinib for BCG-refractory non–muscle invasive bladder cancer with FGFR (fibroblast growth factor receptor) alterations. Patients were randomly assigned 2:1 to receive oral erdafitinib 6 mg daily or investigator’s choice of intravesical chemotherapy. The primary end point was recurrence-free survival (RFS), with secondary end points of 6-month and 12-month RFS.
With median 13-month follow-up, median RFS was not reached with erdafitinib versus 0.28 for chemotherapy, favoring erdafitinib. The 12-month RFS was 77% with erdafitinib versus 41% with chemotherapy. Erdafitinib significantly reduced recurrence in high-risk patients. However, most patients experienced treatment-related adverse events with the oral formulation.
Daneshmand notes that while erdafitinib showed efficacy, the oral toxicity profile is concerning for non–muscle invasive bladder cancer treatment. This paved the way for the TAR-200 study using an intravesical formulation of erdafitinib, which will be discussed later.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
